Lorem ipsum dolor sit amet
![Susan Galbraith Executive Vice President, Oncology R&D, AstraZeneca](/content/dam/az/our-company/Leadership/2024/Susan_Galbraith.jpg/jcr:content/renditions/cq5dam.web.{width}.Susan_Galbraith.jpg)
Susan Galbraith is the Executive Vice President of Oncology R&D at AstraZeneca, with global accountability for the Oncology portfolio from discovery through to late-stage development. Susan is transforming the productivity and scientific output from Oncology R&D, leading the charge for exploring the next wave of cancer treatment regimens, including therapies that directly target cancer cells, others that harness the power of the immune system, and novel combinations that may result in deeper, more durable responses. To date, Susan has been instrumental in bringing 12 cancer medicines to patients.
A Clinical Oncologist by background, Susan trained in medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she was awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research (ICR) in 2017, admitted to Fellowship of the Academy of Medical Sciences in 2018 and elected to the Academy of the American Association for Cancer Research (AACR) in 2024.
Susan is well known in the scientific community for her thought leadership and collaboration with clinicians, academic physicians, governments and the broader pharmaceutical industry. In addition to her role with AstraZeneca, Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021-2024 she served on the Board of Directors of the AACR and currently serves on the European Association of Cancer Research (EACR) Advisory Council.
Publications
From drug development in cancer medicines to diversity in clinical trials, discover the topics Susan has recently contributed to in leading scientific journals.
Awards and accolades
![award](/content/dam/az-jp/what-science-can-do/Ambassadors/Award_Icon.png/jcr:content/renditions/cq5dam.thumbnail.48.48.png)
2024
![award](/content/dam/az/what-science-can-do/Ambassadors/Award_Icon.png/jcr:content/renditions/cq5dam.thumbnail.48.48.png)
2024
![award](/content/dam/az/what-science-can-do/Ambassadors/Award_Icon.png/jcr:content/renditions/cq5dam.thumbnail.48.48.png)
2021-2024
![award](/content/dam/az/what-science-can-do/Ambassadors/Award_Icon.png/jcr:content/renditions/cq5dam.thumbnail.48.48.png)
2018
![award](/content/dam/az/what-science-can-do/Ambassadors/Award_Icon.png/jcr:content/renditions/cq5dam.thumbnail.48.48.png)
2017
![award](/content/dam/az/what-science-can-do/Ambassadors/Award_Icon.png/jcr:content/renditions/cq5dam.thumbnail.48.48.png)
2013
What science can do stories
Authored by, or featuring, Susan Galbraith
Veeva ID: Z4-63069
Date of preparation: May 2024